We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Up 1.3% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Abbott (ABT - Free Report) . Shares have added about 1.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Abbott due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Abbott Laboratories before we dive into how investors and analysts have reacted as of late.
ABT Q3 Earnings Miss, Revenues Rise Y/Y, Margins Up
Abbott reported third-quarter 2026 adjusted earnings per share of $1.42, up 9.2% year over year. The figure missed the Zacks Consensus Estimate by 0.7%.
Sales increased 14.5% year over year to $13.01 billion, surpassing the consensus mark by 0.3%. Comparable sales rose 7%, supported by growth across all four operating segments.
Medical Devices Maintain Growth Momentum
Medical Devices sales increased 6.9% year over year on a reported basis to $5.83 billion. Comparable sales advanced 7.8%, reflecting growth across several cardiovascular and diabetes-care businesses.
Electrophysiology sales climbed 15.5% on a comparable basis, while Rhythm Management and Heart Failure advanced 10% and 6%, respectively. Diabetes Care sales grew 6.7%, supported by a 7.7% increase in continuous glucose monitor (CGM) sales. Vascular sales improved 5.7%, while Structural Heart rose 6.9%. Neuromodulation sales declined 1.1%.
Diagnostics Gain From Cancer Testing
Diagnostics sales surged 46.7% year over year on a reported basis to $3.31 billion, reflecting contributions from the March 2026 acquisition of Exact Sciences. Comparable sales increased 6.4%.
Cancer Diagnostics sales totaled $968 million and grew 13.8% on a comparable basis. Performance benefited from Cologuard growth and contributions from precision oncology and international operations.
Core Laboratory Diagnostics sales increased 5.4%, driven by balanced growth across the United States, Europe, Japan and Latin America. Rapid and Molecular Diagnostics sales improved 0.9% on a comparable basis, supported by modest growth in both domestic and international markets.
Nutrition Business Returns to Growth
Nutrition sales increased 5.1% year over year on a reported basis to $2.26 billion. Comparable sales rose 4.9%, reflecting broad-based improvement across the portfolio.
Pediatric Nutrition sales advanced 8.7% on a comparable basis, while Adult Nutrition increased 1.8%. U.S. Nutrition sales climbed 7.9%, supported by 11% growth in domestic Pediatric Nutrition. International Nutrition sales rose 2.8% on a comparable basis. Total Nutrition revenues also improved sequentially by $118 million from the second quarter of 2026.
EPD Growth Remains Broad-Based
Established Pharmaceuticals sales increased 6.8% year over year on a reported basis to $1.61 billion. Comparable sales grew 8.4%, reflecting continued expansion across international markets.
Key Emerging Markets sales advanced 10.9% on a comparable basis, supported by double-digit growth in India and several Latin American and Asia-Pacific markets. Sales in other markets increased 1.6% on a comparable basis. Key Emerging Markets generated $1.20 billion in quarterly revenues, while other markets contributed $419 million.
Q3 Margin Details
In the third quarter, adjusted gross profit increased 17.4% year over year to $7.45 billion. The adjusted gross margin expanded approximately 143 basis points (bps) to 57.2%.
Adjusted selling, general and administrative expenses increased 16.7% year over year to $3.51 billion. Adjusted research and development expenses grew 22.2% to $892 million. Adjusted operating profit rose 16.9% to $3.05 billion, while the adjusted operating margin expanded approximately 49 bps to 23.4%.
Abbott's 2026 and Q4 Financial Guidance
Abbott tightened its full-year 2026 adjusted earnings guidance to $5.50-$5.55 per share, reaffirming the midpoint of its previous $5.45-$5.60 range.
The company now projects approximately 6% comparable sales growth for 2026 compared with its previous guidance of 6.5%-7.5%.
For the fourth quarter, management expects adjusted EPS of $1.62-$1.67.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, Abbott has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Abbott has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Image: Bigstock
Abbott (ABT) Up 1.3% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Abbott (ABT - Free Report) . Shares have added about 1.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Abbott due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for Abbott Laboratories before we dive into how investors and analysts have reacted as of late.
ABT Q3 Earnings Miss, Revenues Rise Y/Y, Margins Up
Abbott reported third-quarter 2026 adjusted earnings per share of $1.42, up 9.2% year over year. The figure missed the Zacks Consensus Estimate by 0.7%.
Sales increased 14.5% year over year to $13.01 billion, surpassing the consensus mark by 0.3%. Comparable sales rose 7%, supported by growth across all four operating segments.
Medical Devices Maintain Growth Momentum
Medical Devices sales increased 6.9% year over year on a reported basis to $5.83 billion. Comparable sales advanced 7.8%, reflecting growth across several cardiovascular and diabetes-care businesses.
Electrophysiology sales climbed 15.5% on a comparable basis, while Rhythm Management and Heart Failure advanced 10% and 6%, respectively. Diabetes Care sales grew 6.7%, supported by a 7.7% increase in continuous glucose monitor (CGM) sales. Vascular sales improved 5.7%, while Structural Heart rose 6.9%. Neuromodulation sales declined 1.1%.
Diagnostics Gain From Cancer Testing
Diagnostics sales surged 46.7% year over year on a reported basis to $3.31 billion, reflecting contributions from the March 2026 acquisition of Exact Sciences. Comparable sales increased 6.4%.
Cancer Diagnostics sales totaled $968 million and grew 13.8% on a comparable basis. Performance benefited from Cologuard growth and contributions from precision oncology and international operations.
Core Laboratory Diagnostics sales increased 5.4%, driven by balanced growth across the United States, Europe, Japan and Latin America. Rapid and Molecular Diagnostics sales improved 0.9% on a comparable basis, supported by modest growth in both domestic and international markets.
Nutrition Business Returns to Growth
Nutrition sales increased 5.1% year over year on a reported basis to $2.26 billion. Comparable sales rose 4.9%, reflecting broad-based improvement across the portfolio.
Pediatric Nutrition sales advanced 8.7% on a comparable basis, while Adult Nutrition increased 1.8%. U.S. Nutrition sales climbed 7.9%, supported by 11% growth in domestic Pediatric Nutrition. International Nutrition sales rose 2.8% on a comparable basis. Total Nutrition revenues also improved sequentially by $118 million from the second quarter of 2026.
EPD Growth Remains Broad-Based
Established Pharmaceuticals sales increased 6.8% year over year on a reported basis to $1.61 billion. Comparable sales grew 8.4%, reflecting continued expansion across international markets.
Key Emerging Markets sales advanced 10.9% on a comparable basis, supported by double-digit growth in India and several Latin American and Asia-Pacific markets. Sales in other markets increased 1.6% on a comparable basis. Key Emerging Markets generated $1.20 billion in quarterly revenues, while other markets contributed $419 million.
Q3 Margin Details
In the third quarter, adjusted gross profit increased 17.4% year over year to $7.45 billion. The adjusted gross margin expanded approximately 143 basis points (bps) to 57.2%.
Adjusted selling, general and administrative expenses increased 16.7% year over year to $3.51 billion. Adjusted research and development expenses grew 22.2% to $892 million. Adjusted operating profit rose 16.9% to $3.05 billion, while the adjusted operating margin expanded approximately 49 bps to 23.4%.
Abbott's 2026 and Q4 Financial Guidance
Abbott tightened its full-year 2026 adjusted earnings guidance to $5.50-$5.55 per share, reaffirming the midpoint of its previous $5.45-$5.60 range.
The company now projects approximately 6% comparable sales growth for 2026 compared with its previous guidance of 6.5%-7.5%.
For the fourth quarter, management expects adjusted EPS of $1.62-$1.67.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates revision.
VGM Scores
At this time, Abbott has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Abbott has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.